Denosumab-related osteonecrosis of the jaw

Journal of the American Dental Association

Volumn 143, Issue 9, 2012, Pages 981-984

  Diz, Pedro ^a   López Cedrún, José Luis ^b   Arenaz, Jorge ^b   Scully, Crispian ^c  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b HOSPITAL JUAN CANALEJO   (Spain)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Bisphosphonates; Denosumab; Osteonecrosis

Indexed keywords

EID: 84866924171     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2012.0323     Document Type: Article

References (12)

1. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws: 2009 update. J Oral Maxillofac Surg 2009;67(5 suppl):2-12.
2. Khan AA, Sandor GK, Dore E, et al.; Canadian Taskforce on Osteonecrosis of the Jaw. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009;36(3):478-490.
3. Williamson RA. Surgical management of bisphosphonate induced osteonecrosis of the jaws (published online ahead of print Dec. 16, 2009). Int J Oral Maxillofac Surg 2010;39(3):251-255. doi: 10.1016/j.yom.2009.11.014.
4. Migliorati CA, Covington JS 3rd. New oncology drugs and osteonecrosis of the jaw (ONJ). J Tenn Dent Assoc 2009;89(4):36-38.
5. Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 2010;48(3):221-223.
6. Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the jaw in a patient on Denosumab (published online ahead of print Feb. 10, 2010). J Oral Maxillofac Surg 2010;68(5):959-963. doi:10.1016.j joms. 2009.10.010.
7. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases (published online ahead of print Oct. 10, 2011). Ann Oncol 2012;23(5):1341-1347. doi:10:1093/annonc/mdr435.
8. Smith MR, Egerdie B, Hernandez Toriz N, et al; Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer (published online ahead of print Aug. 11,2009). N Engl J Med 2009;361(8):745-755. doi:10.1056/NEJMoa0809003.
9. Cummings SR, San Martin J, McClung MR, et al; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis (published online ahead of print Aug. 11,2009; published correction appears in N Engl J Med 2009;361[19]:1914).
10. N Engl J Med 2009;361(8):756-765. doi:10.1056/NEJMoa0809493.
11. U.S. Food and Drug Administration. Drugs: Approved Risk Evaluation and Mitigation Strategies (REMS)-Prolia (Denosumab) Injection. www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetylnformationforPatientsandProviders/ucmlll350.htm. Accessed Aug. 1, 2012.
12. U.S. Food and Drug Administration. Drugs: Medication Guides-Prolia (Denosumab) (2012 version), www.fda.gov/drugs/drugsafety/ucm085729.htm. Accessed Aug. 1, 2012.